Analysis of 53 Patients With Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL) Treated With CD7-Targeted CAR-T Cell Therapy

Longer observation for a phase I/II clinical trial on a novel fratricide-resistant approach to derive naturally selected 7CAR-T cells (NS7CAR) from bulk T cells without any additional genetic manipulations were discussed at ASH. A total of 53 patients with Ph-positive relapsed/refractory ALL were treated with NS7CAR T-cell therapy using one of three doses. At median follow up of 206 days, 95.8% of patients had achieved minimal residual disease-negative complete remission, as evidenced in peripheral blood and bone marrow.